Scarica l'app Stockscreener
2.05
77.84%
-7.20
Dopo l'orario di chiusura:
2.13
0.08
+3.90%
Lipocine Inc Borsa (LPCN) Ultime notizie
LPCN stock crashes 78%—here’s why - MSN
Lipocine’s Phase 3 Trial Failure Triggers Stock Drop, Strategic Reevaluation - timothysykes.com
LPCN Should I Buy - Intellectia AI
Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint - Sahm
Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results - Sahm
Nasdaq Down 1%; US Initial Jobless Claims Fall - Sahm
Lipocine Inc (ticker: LPCN) announced that its experimental drug for postpartum depression failed to meet the primary endpoint in its Phase III clinical trial, causing the company's stock price to plummet by 78.4% in pre-market trading. - Bitget
Lipocine Tumbles 78.6% Intraday: Is This A Volatility Shock or a Reckoning? - Bitget
LPCN | Lipocine Inc. Insider Trading - Quiver Quantitative
CEO Mahesh Patel Acquires 25,000 Shares of Lipocine Inc (LPCN) - GuruFocus
Lipocine CEO buys 25,000 shares in open market | LPCN Insider Trading - Stock Titan
Oral ‘roid void in PPD? Lipocine MINI bike may have wheels - BioWorld MedTech
LPCN Stock Crashes 78%— Here’s Why - Stocktwits
Lipocine weighs path after LPCN 1154 Phase 3 miss - tipranks.com
Phase 3 PPD trial for Lipocine (NASDAQ: LPCN) drug falls short - Stock Titan
Lipocine stock tumbles after phase 3 trial misses endpoint - Investing.com
Lipocine's postpartum depression pill misses main goal in late-stage study - TradingView
Lipocine reports topline safety & efficacy results for LPCN 1154 in patients with postpartum depression - MarketScreener
Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression - Bitget
Retail Trends: Can Lipocine Inc deliver consistent EPS growth2026 Recap & Real-Time Volume Spike Alerts - baoquankhu1.vn
Will Lipocine's LPCN 1154 Set A New Standard In Postpartum Depression? - RTTNews
Gains Recap: Is Lipocine Inc a cyclical or defensive stockQuarterly Performance Summary & Weekly Stock Performance Updates - baoquankhu1.vn
Aug Mood: What is the Moat Score of Lipocine IncMarket Sentiment Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Lipocine (NASDAQ:LPCN) Rating Increased to Hold at Wall Street Zen - marketbeat.com
If You Invested $1,000 in Lipocine Inc (LPCN) - Stock Titan
LPCN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Lipocine price target raised to $11 from $6.75 at Alliance Global - TipRanks
Lipocine Announces 2025 Financial Results and Progress on Postpartum Depression, Epilepsy, and Obesity Drug Pipeline - Minichart
Lipocine Inc. 2025 Annual Report: Innovative Oral Drug Delivery, CNS & Metabolic Pipeline, and R&D Highlights - Minichart
Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 - The Herald Journal
Lipocine Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Lipocine 2025 Financial Results: Q4 & Annual PerformanceNews and Statistics - IndexBox
Lipocine: Fourth Quarter Financial Results Overview - Bitget
Lipocine: Q4 Earnings Snapshot - Barchart
Lipocine (NASDAQ: LPCN) 2025 revenue falls to $2M with $9.6M loss - Stock Titan
LPCN: 2025 saw a net loss of $9.6M as revenue fell, with cash runway through Q1 2027 and ongoing R&D focus - TradingView
Lipocine 10-K: Revenue $2.0M, EPS (Basic) $(1.77) - TradingView
Lipocine Inc expected to post a loss of 61 cents a shareEarnings Preview - TradingView
Is Lipocine Inc affected by consumer sentiment2026 Performance Recap & Weekly Setup with High ROI Potential - baoquankhu1.vn
AI Stocks: Will Lipocine Inc benefit from rate cuts2025 Support & Resistance & Daily Profit Maximizing Tips - baoquankhu1.vn
Lipocine Stock Quote, Share Price, News and Analysis - Longbridge
Lipocine Files Prospectus to Enable $50M Stock Offering - The Globe and Mail
Lipocine (LPCN) Expected to Announce Earnings on Thursday - Defense World
Lipocine (LPCN) establishes $50M at-the-market common stock sales plan - Stock Titan
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) - Nasdaq
Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock? - Yahoo Finance
Lipocine Files For Common Stock Offering Of Up To $50 MillionSEC Filing - TradingView
LivePerson (NASDAQ: LPCN) increases ATM sales capacity to $50M - Stock Titan
Lipocine (LPCN) Jumps 5.5%: Does the Stock Have More Room to Grow? - Bitget
ETF Watch: Is Lipocine Inc a turnaround storyTreasury Yields & Daily Momentum Trading Reports - baoquankhu1.vn
Can Lipocine Inc. stock beat market expectations this quarterTreasury Yields & Short-Term High Return Ideas - mfd.ru
Lipocine completes patient visits in phase 3 trial for PPD treatment - Investing.com Australia
Lipocine completes patient visits in phase 3 trial for PPD treatment By Investing.com - Investing.com South Africa
Lipocine Completes Phase 3 Trial for Postpartum Depression - TipRanks
Lipocine (NASDAQ: LPCN) files updated corporate investor presentation - Stock Titan
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):